Benzinga · Jul 17, 2026
Bone Biologics Files Prospectus To Offer Up To 6.46M Shares Of Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1419554/000149315226033789/forms-3.htm

NASDAQ · BBLG
Healthcare · Medical - Devices
$0.67
Up+$0.02 (+2.48%)
Updated Aug 14, 2026, 6:23 AM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BBLG closed at $0.67 after 21 trading sessions, down 43.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $0.655 | $0.678 | $0.62 | $0.6743 | 674.56K |
| Aug 12, 2026 | $0.6734 | $0.7283 | $0.62 | $0.658 | 15.24M |
| Aug 11, 2026 | $0.908 | $0.975 | $0.85 | $0.9088 | 22.09K |
| Aug 10, 2026 | $0.9327 | $0.945 | $0.83 | $0.8796 | 24.77K |
| Aug 7, 2026 | $0.9883 | $0.9884 | $0.8919 | $0.9325 | 35.11K |
| Aug 6, 2026 | $0.982 | $0.9901 | $0.9194 | $0.9194 | 13.36K |
| Aug 5, 2026 | $0.98 | $1.04 | $0.9441 | $0.98 | 50.01K |
| Aug 4, 2026 | $0.9242 | $1.06 | $0.91 | $0.9451 | 98.74K |
| Aug 3, 2026 | $0.8457 | $0.93 | $0.8377 | $0.90 | 90.84K |
| Jul 31, 2026 | $0.86 | $0.86 | $0.83 | $0.8457 | 19.31K |
| Jul 30, 2026 | $0.88 | $0.888 | $0.843 | $0.8601 | 38.58K |
| Jul 29, 2026 | $0.9504 | $0.9504 | $0.8801 | $0.9046 | 20.39K |
| Jul 28, 2026 | $1.04 | $1.04 | $0.94 | $0.9612 | 32.46K |
| Jul 27, 2026 | $1.08 | $1.09 | $1.01 | $1.025 | 80.57K |
| Jul 24, 2026 | $1.11 | $1.14 | $1.05 | $1.07 | 12.17K |
| Jul 23, 2026 | $1.11 | $1.15 | $1.074 | $1.08 | 10.74K |
| Jul 22, 2026 | $1.1101 | $1.12 | $1.09 | $1.10 | 28.2K |
| Jul 21, 2026 | $1.1301 | $1.14 | $1.10 | $1.11 | 25.05K |
| Jul 20, 2026 | $1.1701 | $1.18 | $1.12 | $1.12 | 11.82K |
| Jul 17, 2026 | $1.225 | $1.225 | $1.15 | $1.17 | 24.11K |
| Jul 16, 2026 | $1.25 | $1.25 | $1.15 | $1.20 | 31.1K |
The latest Smart Investors Daily articles mentioning BBLG.
BBLG research
Company profile and research snapshot.
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 13, 2023 | EF Hutton | Buy | — |
| Apr 3, 2023 | EF Hutton | Buy | — |
| Oct 18, 2022 | EF Hutton | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 17, 2026
https://www.sec.gov/Archives/edgar/data/1419554/000149315226033789/forms-3.htm
Benzinga · Mar 3, 2026
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03032026_BBLG_Sorensen.pdf
Yahoo · Jan 8, 2026
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. “We executed wit
defenseworld.net · Dec 11, 2025
Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report)'s share price fell 0.5% during trading on Wednesday. The stock traded as low as $1.9246 and last traded at $2.10. 43,801 shares were traded during trading, an increase of 8% from the average session volume of 40,407 shares. The stock had previously closed at $2.11. Analyst
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning BBLG.